Skip to content

JL PHARMA

Active Private limited companyfounded 2020active for 6 yearsChession 32, 4987 StoumontKBO/BCE: BE 0743.926.553

Lifetime

6 annual accounts with figures on one time axis
peak of €15,959 in 2022
€15,096▲ 2.0%
peak of €7,135 in 2021
€5,740▲ 59.7%
peak of €24,794 in 2022
€10,746▲ 24.9%
€11,861▼ 35.1%
Board1 name since 2020
1 director
Documentsfilings and deeds
18-06-202643 days before the deadline
2025micro format
Result from €3,595 to €5,740Dividend €3,600Equity from €8,606 to €10,746Debts from €18,265 to €11,861

Key points

from the 2025 annual accounts

Equity

€10,746 ▲ 24.9%
8,6062024+5,740Profit-3,600Dividend10,7462025

JL PHARMA paid out €3,600 in dividends. That is 63% of the 2025 profit.

Liquidity

1.90 was 1.22 in 2024

Short-term debts fell from €18,265 to €11,861.

Filings

6 annual accounts since 2020
AprilJune31 JulyOctober202020222024

The last five annual accounts were filed 17 to 43 days before the end of the period.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 26,977 companies had the same profile as JL PHARMA has now. Each dot stands for 68 companies, two years later.

94.9%
were still trading
3.5%
stopped another way
1.6%
went bankrupt
  • Micro
  • 5 to 10 years old
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more

Another 0.1% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 497,965 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 26,977 companies, not a prediction for JL PHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director, since 20-02-2020
  • 100 sharesdeed of 24-02-2020
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0743926553
First establishment Chession 32, Stoumont
Incorporation Founding capital of €5,000, 50 shares · Founded by · appointed as director · published on 24-02-2020 · Gazette deed
All 11 events

Comparable companies

same main activity, similar in size and age
Company
JL PHARMA Stoumont €22,608 €15,096 47.5% -
PHARMAXUS Zandhoven €25,186 €19,190 26.0% -
LORENA BOULANGER PHARMA Chapelle-lez-Herlaimont €32,165 €14,597 80.6% -
Farmaco Ranst €17,325 €22,129 5.8% -
DEL PHARMA Mons €36,943 €19,174 44.1% -
Quantum Satis Zele €34,289 €11,208 56.5% -
PharmAzzy Zonhoven €37,787 €15,793 67.3% -

These companies have the same main activity as JL PHARMA: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €17,300 and €37,800, founded between 2018 and 2022.

Official details

Source: KBO
Status
Active since 20-02-2020Normal situation
Activity
Retail sale of pharmaceutical productsNACE 47730
Establishment unit
2.299.488.5324987 Stoumont, since 01-03-2020
Financial year end
31 December
Peppol
Reachable since 18-12-2025
Company details

Annual accounts 2025

≈ €160,000estimated
€22,608▼ 15.9%
Filing
Filed on 18-06-2026, 43 days before the end of the filing period
Financials

Insights on JL PHARMA

JL PHARMA files the micro format. That format states no turnover. The gross margin rose from €10,820 in 2020 to €15,096 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about JL PHARMA

What is the company number of JL PHARMA?
The company number of JL PHARMA is 0743.926.553. The VAT number is the same number with BE in front: BE 0743.926.553.
Where is JL PHARMA based?
The registered office is at Chession 32, 4987 Stoumont.Company details
What does JL PHARMA do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of JL PHARMA?
JL PHARMA is a private limited company (BV).
When was JL PHARMA founded?
JL PHARMA was founded on 20-02-2020.
Is JL PHARMA still active?
Yes, JL PHARMA is an active enterprise in the KBO register.
What is the turnover of JL PHARMA?
The turnover in financial year 2025 is ≈ €160,000. This figure is estimated from the gross margin of €15,096 and 139 comparable companies (NACE 477). It probably lies between €58,000 and €340,000. It is a rough estimate.Financials
Is JL PHARMA profitable?
In financial year 2025, JL PHARMA made a profit of €5,740.
Where can I find the annual accounts of JL PHARMA?
JL PHARMA filed 6 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of JL PHARMA due?
JL PHARMA must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.